LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Heron Therapeutics Inc

Heron Therapeutics Inc

Suletud

Sektor Tervishoid

1.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.78

Max

1.8

Põhinäitajad
By Trading Economics
Sissetulek	-25M
Müük	2.8M 34M
Aktsiakasum	-0.07
Kasumimarginaal	-79.557
Töötajad	126
EBITDA	-24M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+233.33 upside

Turustatistika
By TradingEconomics
Turukapital	1.5M 421M
Eelmine avamishind	1.79
Eelmine sulgemishind	1.79

Uudiste sentiment

By Acuity

50%

94 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

1.799 / 1.93 Toetus ja vastupanu

Heron Therapeutics Inc Graafik

Seotud uudised

24. jaan 2024, 15:35 UTC

Suurimad hinnamuutused turgudel

Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

233.33% tõus

12 kuu keskmine prognoos

Keskmine 6 USD 233.33%

Kõrge 7 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.799 / 1.93Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

94 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.